Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Ahmadzadeh, 2009, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 114, 1537, 10.1182/blood-2008-12-195792 Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma, N. Engl. J. Med., 372, 311, 10.1056/NEJMoa1411087 Baitsch, 2012, Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization, PLoS ONE, 7, e30852, 10.1371/journal.pone.0030852 Barber, 2006, Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, 439, 682, 10.1038/nature04444 Benson, 2014, Killer immunoglobulin-like receptors and tumor immunity, Cancer Immunol Res, 2, 99, 10.1158/2326-6066.CIR-13-0219 Blackburn, 2009, Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection, Nat. Immunol., 10, 29, 10.1038/ni.1679 Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J. Clin. Oncol., 28, 3167, 10.1200/JCO.2009.26.7609 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N. Engl. J. Med., 366, 2455, 10.1056/NEJMoa1200694 Butte, 2007, Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses, Immunity, 27, 111, 10.1016/j.immuni.2007.05.016 Chambers, 1998, Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells, Eur. J. Immunol., 28, 3137, 10.1002/(SICI)1521-4141(199810)28:10<3137::AID-IMMU3137>3.0.CO;2-X Chapoval, 2001, B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production, Nat. Immunol., 2, 269, 10.1038/85339 Chavin, 2009, Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases, Clin. Cancer Res., 15, 2174, 10.1158/1078-0432.CCR-08-2262 Crispen, 2008, Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma, Clin. Cancer Res., 14, 5150, 10.1158/1078-0432.CCR-08-0536 Curiel, 2003, Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity, Nat. Med., 9, 562, 10.1038/nm863 Dijkstra, 2006, Identification and characterization of a second CD4-like gene in teleost fish, Mol. Immunol., 43, 410, 10.1016/j.molimm.2005.03.005 Dong, 1999, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, Nat. Med., 5, 1365, 10.1038/70932 Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat. Med., 8, 793, 10.1038/nm0902-1039c Durham, 2014, Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo, PLoS ONE, 9, e109080, 10.1371/journal.pone.0109080 Fallarino, 1998, B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28, J. Exp. Med., 188, 205, 10.1084/jem.188.1.205 Fallarino, 2006, The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells, J. Immunol., 176, 6752, 10.4049/jimmunol.176.11.6752 Fleury, 1991, Mutational analysis of the interaction between CD4 and class II MHC: class II antigens contact CD4 on a surface opposite the gp120-binding site, Cell, 66, 1037, 10.1016/0092-8674(91)90447-7 Fong, 2009, Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF, Cancer Res., 69, 609, 10.1158/0008-5472.CAN-08-3529 Fu, 2014, Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors, Cancer Res., 74, 4042, 10.1158/0008-5472.CAN-13-2685 Goldberg, 2007, Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells, Blood, 110, 186, 10.1182/blood-2006-12-062422 Grosso, 2007, LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems, J. Clin. Invest., 117, 3383, 10.1172/JCI31184 Grosso, 2009, Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells, J. Immunol., 182, 6659, 10.4049/jimmunol.0804211 Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N. Engl. J. Med., 369, 134, 10.1056/NEJMoa1305133 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466 Honda, 2014, Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues, Immunity, 40, 235, 10.1016/j.immuni.2013.11.017 Huang, 2004, Role of LAG-3 in regulatory T cells, Immunity, 21, 503, 10.1016/j.immuni.2004.08.010 Huang, 2015, CEACAM1 regulates TIM-3-mediated tolerance and exhaustion, Nature, 517, 386, 10.1038/nature13848 Huard, 1994, Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand, Immunogenetics, 39, 213, 10.1007/BF00241263 Huard, 1997, Characterization of the major histocompatibility complex class II binding site on LAG-3 protein, Proc. Natl. Acad. Sci. USA, 94, 5744, 10.1073/pnas.94.11.5744 Johnston, 2014, The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function, Cancer Cell, 26, 923, 10.1016/j.ccell.2014.10.018 Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu. Rev. Immunol., 26, 677, 10.1146/annurev.immunol.26.021607.090331 Kisielow, 2005, Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells, Eur. J. Immunol., 35, 2081, 10.1002/eji.200526090 Kwon, 2014, Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial, Lancet Oncol., 15, 700, 10.1016/S1470-2045(14)70189-5 Latchman, 2001, PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat. Immunol., 2, 261, 10.1038/85330 Leach, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science, 271, 1734, 10.1126/science.271.5256.1734 Lenschow, 1996, CD28/B7 system of T cell costimulation, Annu. Rev. Immunol., 14, 233, 10.1146/annurev.immunol.14.1.233 Lines, 2014, VISTA is an immune checkpoint molecule for human T cells, Cancer Res., 74, 1924, 10.1158/0008-5472.CAN-13-1504 Linsley, 1994, Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors, Immunity, 1, 793, 10.1016/S1074-7613(94)80021-9 Liu, 2012, Densely granulated murine NK cells eradicate large solid tumors, Cancer Res., 72, 1964, 10.1158/0008-5472.CAN-11-3208 Llosa, 2015, The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov., 5, 43, 10.1158/2159-8290.CD-14-0863 Loo, 2012, Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity, Clin. Cancer Res., 18, 3834, 10.1158/1078-0432.CCR-12-0715 Luo, 2004, B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells, J. Immunol., 173, 5445, 10.4049/jimmunol.173.9.5445 Lynch, 2012, Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study, J. Clin. Oncol., 30, 2046, 10.1200/JCO.2011.38.4032 Maker, 2005, Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade, J. Immunol., 175, 7746, 10.4049/jimmunol.175.11.7746 Maker, 2006, Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma, J. Immunother., 29, 455, 10.1097/01.cji.0000208259.73167.58 Marcus, 2014, Recognition of tumors by the innate immune system and natural killer cells, Adv. Immunol., 122, 91, 10.1016/B978-0-12-800267-4.00003-1 Marzec, 2008, Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1), Proc. Natl. Acad. Sci. USA, 105, 20852, 10.1073/pnas.0810958105 Matsuzaki, 2010, Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer, Proc. Natl. Acad. Sci. USA, 107, 7875, 10.1073/pnas.1003345107 Mellor, 2004, IDO expression by dendritic cells: tolerance and tryptophan catabolism, Nat. Rev. Immunol., 4, 762, 10.1038/nri1457 Moebius, 1993, Delineation of an extended surface contact area on human CD4 involved in class II major histocompatibility complex binding, Proc. Natl. Acad. Sci. USA, 90, 8259, 10.1073/pnas.90.17.8259 Monney, 2002, Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease, Nature, 415, 536, 10.1038/415536a Motzer, 2014, Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial, J. Clin. Oncol., 10.1200/jco.2014.32.15_suppl.5009 Nishimura, 1999, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity, 11, 141, 10.1016/S1074-7613(00)80089-8 Nishimura, 2001, Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice, Science, 291, 319, 10.1126/science.291.5502.319 Okazaki, 2011, PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice, J. Exp. Med., 208, 395, 10.1084/jem.20100466 Park, 2010, B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance, Blood, 116, 1291, 10.1182/blood-2010-01-265975 Parry, 2005, CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms, Mol. Cell. Biol., 25, 9543, 10.1128/MCB.25.21.9543-9553.2005 Parsa, 2007, Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma, Nat. Med., 13, 84, 10.1038/nm1517 Peggs, 2009, Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies, J. Exp. Med., 206, 1717, 10.1084/jem.20082492 Phan, 2003, Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, Proc. Natl. Acad. Sci. USA, 100, 8372, 10.1073/pnas.1533209100 Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904 Prendergast, 2014, Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer, Cancer Immunol. Immunother., 63, 721, 10.1007/s00262-014-1549-4 Qureshi, 2011, Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4, Science, 332, 600, 10.1126/science.1202947 Reck, 2013, Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial, Ann. Oncol., 24, 75, 10.1093/annonc/mds213 Ribas, 2013, Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, J. Clin. Oncol., 31, 616, 10.1200/JCO.2012.44.6112 Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N. Engl. J. Med., 364, 2517, 10.1056/NEJMoa1104621 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N. Engl. J. Med., 372, 320, 10.1056/NEJMoa1412082 Romagné, 2009, Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells, Blood, 114, 2667, 10.1182/blood-2009-02-206532 Rudd, 2009, CD28 and CTLA-4 coreceptor expression and signal transduction, Immunol. Rev., 229, 12, 10.1111/j.1600-065X.2009.00770.x Sakuishi, 2010, Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, J. Exp. Med., 207, 2187, 10.1084/jem.20100643 Sánchez-Fueyo, 2003, Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance, Nat. Immunol., 4, 1093, 10.1038/ni987 Schadendorf, 2015, Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma, J. Clin. Oncol., 10.1200/JCO.2014.56.2736 Schneider, 2006, Reversal of the TCR stop signal by CTLA-4, Science, 313, 1972, 10.1126/science.1131078 Schwartz, 1992, Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy, Cell, 71, 1065, 10.1016/S0092-8674(05)80055-8 Sega, 2014, Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation, PLoS ONE, 9, e86551, 10.1371/journal.pone.0086551 Selby, 2013, Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells, Cancer Immunol Res, 1, 32, 10.1158/2326-6066.CIR-13-0013 Sfanos, 2009, Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+, Prostate, 69, 1694, 10.1002/pros.21020 Shin, 2003, Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor, J. Exp. Med., 198, 31, 10.1084/jem.20030242 Shin, 2005, In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses, J. Exp. Med., 201, 1531, 10.1084/jem.20050072 Slovin, 2013, Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study, Ann. Oncol., 24, 1813, 10.1093/annonc/mdt107 Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N. Engl. J. Med., 371, 2189, 10.1056/NEJMoa1406498 Soliman, 2014, A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors, Oncotarget, 5, 8136, 10.18632/oncotarget.2357 Spranger, 2013, Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells, Sci. Transl. Med., 5, 200ra116, 10.1126/scitranslmed.3006504 Spranger, 2014, Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment, J. Immunother. Cancer, 10.1186/2051-1426-2-3 Steidl, 2011, MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers, Nature, 471, 377, 10.1038/nature09754 Suh, 2003, The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses, Nat. Immunol., 4, 899, 10.1038/ni967 Sun, 2002, Characterization of mouse and human B7-H3 genes, J. Immunol., 168, 6294, 10.4049/jimmunol.168.12.6294 Taube, 2012, Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci. Transl. Med., 4, 127ra37, 10.1126/scitranslmed.3003689 Taube, 2014, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin. Cancer Res., 20, 5064, 10.1158/1078-0432.CCR-13-3271 Tivol, 1995, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, 3, 541, 10.1016/1074-7613(95)90125-6 Topalian, 2014, Balance and imbalance in the immune system: life on the edge, Immunity, 41, 682, 10.1016/j.immuni.2014.11.005 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690 Topalian, 2014, Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J. Clin. Oncol., 32, 1020, 10.1200/JCO.2013.53.0105 Triebel, 1990, LAG-3, a novel lymphocyte activation gene closely related to CD4, J. Exp. Med., 171, 1393, 10.1084/jem.171.5.1393 Tseng, 2001, B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells, J. Exp. Med., 193, 839, 10.1084/jem.193.7.839 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 Wang, 2011, VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses, J. Exp. Med., 208, 577, 10.1084/jem.20100619 Waterhouse, 1995, Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4, Science, 270, 985, 10.1126/science.270.5238.985 Weber, 2014, Current perspectives on immunotherapy, Semin. Oncol., 41, S14, 10.1053/j.seminoncol.2014.09.003 Wing, 2008, CTLA-4 control over Foxp3+ regulatory T cell function, Science, 322, 271, 10.1126/science.1160062 Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin. Cancer Res., 15, 7412, 10.1158/1078-0432.CCR-09-1624 Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N. Engl. J. Med., 369, 122, 10.1056/NEJMoa1302369 Woo, 2012, Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape, Cancer Res., 72, 917, 10.1158/0008-5472.CAN-11-1620 Workman, 2009, LAG-3 regulates plasmacytoid dendritic cell homeostasis, J. Immunol., 182, 1885, 10.4049/jimmunol.0800185 Xiao, 2014, RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance, J. Exp. Med., 211, 943, 10.1084/jem.20130790 Yang, 2007, Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis, J. Immunother., 30, 825, 10.1097/CJI.0b013e318156e47e Yi, 2009, Fine tuning the immune response through B7-H3 and B7-H4, Immunol. Rev., 229, 145, 10.1111/j.1600-065X.2009.00768.x Yu, 2009, The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells, Nat. Immunol., 10, 48, 10.1038/ni.1674 Zhu, 2005, The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity, Nat. Immunol., 6, 1245, 10.1038/ni1271